Xiansheng Pharmaceutical (2096.HK) is an innovation and R&D-driven pharmaceutical company with the "National Key Laboratory of Neurological and Oncology Drug R&D". The company focuses on the fields of tumors, nervous system, autoimmune and anti-infection, and is also actively and proactively planning for the fields of diseases with major clinical needs in the future, and is committed to allowing patients to use more effective drugs as soon as possible. The company has established strategic partnerships with many innovative enterprises and research institutions through the dual-wheel drive of independent research and development and collaborative innovation.